Antigenic fragments of human factor VIII polypeptides

Details Antigenic fragments of human factor VIII polypeptides Antigenic fragments of human factor VIII polypeptides

2011-07-19

2011-07-19

Szperka, Michael (Department: 1644)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S326000, C530S806000, C424S140100, C435S007100, C435S007920

Reexamination Certificate

active

07981865

ABSTRACT:
Antigenic fragments of human Factor VIII polypeptide, pharmaceutical compositions which contain these fragments, and complexes containing these peptides and a carrier protein or peptide.

REFERENCES:
patent: 4965199 (1990-10-01), Capon et al.
patent: 6866848 (2005-03-01), Laub et al.
patent: 0202853 (1986-11-01), None
patent: 62012722 (1987-01-01), None
patent: WO 88/00831 (1988-02-01), None
patent: WO 9602572 (1996-02-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 02060917 (2002-08-01), None
Foster et al. , Blood, 1990, 75:1999-2004.
Foster et al., J. Biol. Chem., 1988, 263:5230-5234.
Levinson et al., Genomics 1992, 14:585-589.
Campbell, A., Monoclonal Antibody Technology, 1984, Elsevier Science Publishers, pp. 1-32.
Algiman, M., et al. (1992) Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc. Natl. Acad. Sci. USA 89:3795-3799.
Dietrich, G., et al. (1992) Origin of Anti-idiotypic Activity Against Anti-factor VIII Autoantibodies in Pools of Normal Human Immunoglobulin G (IVIg). Blood 79:2946-2951.
Ewenstein, B. M., et al. (2000) Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica 85 (Suppl. 10):35-39.
Foster, P. A. et al. (1989) Factor VIII Structure and Function. Blood Reviews 3:180-191.
Janin, J. (1979) Surface and inside volumes in globular proteins. Nature 277:491-492.
Karplus, P. A. et al. (1985) Prediction of Chain Flexibility in Proteins. Naturwissenschaften 72:212-213.
Knobl, P. and Derfler, K. (1999) Extracoporeal Immunoadsorption for the Treatment of Haemophilic Patients with Inhibitors to Factor VIII or IX. Vox Sanguinis 77 (Suppl. 1):57-64.
Laub, R., et al. (1999) Inhibitors in German Hemophilia A Patients Treated with a Double Virus Inactivated Factor VIII Concentrate Bind to the C2 Domain in FVIII Light Chain. Thromb. Haemost. 81:39-44.
Lollar, P. (2000) Mapping factor VIII inhibitor epitopes using hybrid human/porcine factor VIII molecules. Haematologica 85 (Suppl. 10):26-30.
Moreau, A., et al. (2000) Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood 95:3435-3441.
Morrisson, A. E. and Ludlam C. A. (1995) Acquired Haemophilia and its Management. Br. J. Haematol. 89:231-236.
Palmer, D. S., et al. (1997) Identification of Novel Factor VIII Inhibitor Epitopes using Synthetic Peptide Arrays. Vox Sanguinis 72:148-161.
Parker, J. M. R., et al. (1986) New Hydrophilicity Scale Derived from High-Performance Liquid Chromatography Peptide Retention Data: Correlation of Predicted Surface Residues with Antigenicity and X-ray-Derived Accessible Sites. Biochem. 25:5425-5432.
Peerlinck, K., et al. (1997) Factor VIII Inhibitors in Previously Treated Haemophilia A Patients with a Double Virus-inactivated Plasma Derived Factor VIII Concentrate. Throm. Haemost. 77:80-86.
Pemberton, S., et al. (1997) A Molecular Model for the Triplicated A Domains of Human Factor VIII Based on the Crystal Structure of Human Ceruloplasmin. Blood 89(7):2413-2421.
Pratt, K. P. (2000) Relating structure to function: The role of the C2 domain in Factor VIII. Curr. Opinion Drug Discovery & Development 3(5):516-526.
Raut, S., et al. (1998) Modification of Factor VIII in Therapeutic Concentrates after Virus Inactivation by Solvent-Detergent and Pasteurisation. Throm. Haemost. 80:624-631.
Reding, M. T., et al. (2000) Sensitization of CD4+T Cells to Coagulation Factor VIII: Response in Congenital and Acquired Hemophilia Patients and in Healthy Subjects. Thromb. Haemost. 84:643-652.
Reisner, H. M., et al. (1995) Immunogentics of the human immune response to factor VIII. Aledort, L. M., et al., eds. Inhibitors to Coagulation Factors. New York, NY: Plenum Press pp. 65-78.
Saenko, E. L., et al. (1999) Role of Activation of the Coagulation Factor VIII in Interaction with vWf, Phospholipid, and Functioning within the Factor Xase Complex. TCM 9:185-192.
Scandella, D. H. (2000) Properties of Anti-Factor VIII Inhibitor Antibodies in Hemophilia A Patients. Semin. Thromb. Haemost. 26(2):137-142.
Shima, M., et al. (1991) Epitope localization of monoclonal antibodies against factor VIII light chain which inhibit complex formation by factor VIII with von Williebrand factor. Intl. J. Haematol. 54:515-522.
Toole, J. J., et al. (1984) Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312:342-347.
Tuddenham, E. G. D. and McVey, J. H. (1998) The genetic basis of inhibitor development in haemophilia A. Haemophilia 4:543-545.
Van Den Brink, E. N., et al. (2000) Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. Blood. 95(2):558-563.
Van Regenmortel, M. H. V. (1996) Mapping Epitope Structure and Activity: From One-Dimensional Prediction to Four-Dimensional Description of Antigenic Specificity. Methods: A Companion to Methods in Enzymology 9:465-472.
Vehar, G. A., et al. (1984) Structure of human factor VIII. Nature 312:337-342.
Vermylen, J. (1998) How do some haemophiliacs develop inhibitors? Hemophilia 4:538-542.
Nogami et al., Anticoagulant effects of a synthetic peptide containing residues Thr-22S3-Gln-2270 within factor VIII C2 domain that selectively inhibits factor Xa-catalysed factor VIII activation, British Journal of Haematology, vol. 116, pp. 868-874, 2002.
Nishiya et al., Anticoagulant Effect of a Synthetic Peptide Containing Residues THR2253-GLN2270 Within Factor VIII C2 Domain Which Selectively Inhibits Factor Xa-Catalyzed Factor VIII Activation, Blood, vol. 96, p. 632a, Nov. 16, 2000.
Nogami et al., Role of Factor VIII C2 Domain in Factor VIII Binding to Factor Xa, J. Biol. Chem. 274, pp. 31000-31007, Oct. 22, 1999.
Villard et al., Low Molecular Weight Peptides Restore the Procoagulant Activity of Factor VIII in the Presence of the Potent Inhibitor Antibody ESH8, The Journal of Biological Chemistry, vol. 277, No. 30, pp. 27232-27239, 2002.
Di Giambattista et al., Mapping of Natural Anti-Factor VIII Antibodies in Plasma Pools from Healthy Donors: Use of Rationally Designed Synthetic Peptides, Biologicals, vol. 29, pp. 229-232, 2001.
Di Giambattista et al., In silico prediction of FVIII epitopes recognised by natural autoantibodies in polyvalent immunoglobulin concentrates, Molecular Immunology, vol. 44, pp. 1903-1913, 2007.
Eaton et al, Construction and Characterization of an Active Factor VIII Variant Lacking the Central One-Third of the Molecule, Biochemistry, vol. 25, No. 26, pp. 8343-8347, 1986.
Foster et al, A Synthetic Factor VIII Peptide of Eight Amino Acid Residues (1677-1684) Contains the Binding Region of an Anti-Factor VIII Antibody which Inhibits the Binding of Factor VIII to von Willebrand Factor, Thrombosis and Haemostasis, vol. 63, pp. 403-406, 1990.
Jones et al, 2005, Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII, Journal of Thrombosis and Haemostasis, vol. 3, pp. 991-1000.
Lubahn et al., Identification of a F.VIII epitope recognized by a human hemophilic inhibitor, Blood, vol. 73, No. 2, pp. 497-499, 1989.
Muelien et al., A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII, Protein Engineering, vol. 2, No. 4, pp. 301-306, 1988.
Reding et al., Epitope repertoire of human CD4+T cells on the A3 domain of coagulation factor VIII, Journal of Thrombosis and Haemostasis, vol. 2, pp. 1385-1394, 2004.
Shima et al., Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor., British Journal of Haematology, 1995, 91, pp. 714-721.
Lewis et al., Phospholipid vesicles interfere with the binding of antibody fragments to the light chain of factor VIII, Thromb Haemost 2005; 93: pp. 833-41.
Saenko et al., Slowed Release of Thrombin-cleaved Factor VIII from von Willebrand Factor by a Monoclonal and a Human Antibody Is a Novel Mechanism for Factor VIII Inhibition, Journal of Biological Chemistry, vol. 271, No. 44, Nov. 1, pp. 27424-27431, 1996.
Scandella et al.

Affiliated with

Also associated with

Rating

Antigenic fragments of human factor VIII polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antigenic fragments of human factor VIII polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigenic fragments of human factor VIII polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2665239